Skip to main content

Table 1 Comparison of levels of soluble protein biomarkers (VEGF, sVEGFR-2, and PlGF) at baseline and at the end of the first treatment cycle (day 28 of cycle 1) in RCC patients. Only readings that were in the assay detection range are included in this table.

From: Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins

 

Mean

Median

Range (pg/mL)

VEGF

   

Cycle 1, Day 1 (n = 62)

86.9

67.0

9.7 – 355.5

Cycle 1, Day 28 (n = 55)

278.7

193.3

26.1 – 973.9

sVEGFR-2

   

Cycle 1, Day 1 (n = 62)

9610.3

9554.5

6390 – 14496.5

Cycle 1, Day 28 (n = 57)

5303.9

5157.0

1948 – 11241.5

PlGF*

   

Cycle 1, Day 1 (n = 17)

41.7

35.6

26.7 – 95.9

Cycle 1, Day 28 (n = 53)

111.8

77.9

29.0 – 483.3